A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma

Abstract

BACKGROUND CEA is expressed in >90% of pancreatic cancers (PC) and may be an appropriate immunotherapy target. CEA is poorly immunogenic due to immune tolerance; CAP1-6D, an altered peptide ligand can help bypass tolerance. We conducted a pilot randomized phase I trial in PC patients to determine the peptide dose required to induce an optimal CD8(+) T cell… (More)
DOI: 10.1186/2051-1426-1-8

Topics

6 Figures and Tables

Statistics

0100200300201520162017
Citations per Year

Citation Velocity: 50

Averaging 50 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@inproceedings{Geynisman2013ARP, title={A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma}, author={Daniel M. Geynisman and Yuanyuan Zha and Rangesh Kunnavakkam and Mebea Aklilu and Daniel V. T. Catenacci and Blase Polite and Cara Rosenbaum and Azadeh Namakydoust and Theodore G. Karrison and Thomas F Gajewski and Hedy Lee Kindler}, booktitle={Journal for immunotherapy of cancer}, year={2013} }